David M Hyman Selected Research

David M Hyman Research Topics

Disease

104	Neoplasms (Cancer) 03/2024 - 11/2011
15	Ovarian Neoplasms (Ovarian Cancer) 09/2019 - 06/2012
14	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2016
13	Disease Progression 01/2022 - 08/2015
6	Endometrial Neoplasms (Endometrial Cancer) 01/2020 - 06/2012
6	Melanoma (Melanoma, Malignant) 01/2020 - 08/2015
5	Neoplasm Metastasis (Metastasis) 01/2020 - 10/2016
5	Microsatellite Instability 01/2020 - 01/2018
5	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 08/2015
4	Leiomyosarcoma 01/2020 - 06/2012
4	Erdheim-Chester Disease 01/2020 - 08/2015
4	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2018
4	Histiocytosis 12/2019 - 02/2016
4	Carcinoma (Carcinomatosis) 07/2017 - 11/2011
3	Adenocarcinoma 03/2024 - 11/2015
3	Glioma (Gliomas) 01/2019 - 01/2018
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2020 - 06/2012
2	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2020 - 01/2019
2	Nausea 01/2020 - 08/2017
2	Hemorrhage 09/2019 - 01/2011
2	Adenocarcinoma of Lung 08/2019 - 01/2017
2	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 08/2015
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 08/2015
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2018 - 10/2017
2	Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell) 03/2018 - 08/2015
2	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 07/2014
2	Cholangiocarcinoma 01/2018 - 08/2015
2	Multiple Myeloma 01/2018 - 08/2017
2	Prostatic Neoplasms (Prostate Cancer) 07/2017 - 01/2011
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022
1	Hyperhomocysteinemia 05/2020
1	Retinal Vein Occlusion 05/2020
1	Exanthema (Rash) 01/2020
1	Diarrhea 01/2020
1	Hyperglycemia 01/2020

Drug/Important Bio-Agent (IBA)

22	Phosphotransferases (Kinase)IBA 12/2021 - 02/2016
21	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2016
11	PlatinumIBA 11/2020 - 11/2011
9	larotrectinibIBA 12/2021 - 01/2017
9	Biomarkers (Surrogate Marker)IBA 01/2020 - 12/2015
7	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2020 - 12/2015
7	Estrogen ReceptorsIBA 01/2020 - 07/2017
6	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2015
6	VemurafenibIBA 01/2020 - 08/2015
5	capivasertibIBA 01/2022 - 07/2017
5	Cell-Free Nucleic AcidsIBA 01/2021 - 01/2017
5	neratinibIBA 10/2020 - 01/2017
5	human ERBB2 proteinIBA 01/2020 - 10/2016
4	Trastuzumab (Herceptin)FDA Link 03/2024 - 12/2017
4	TropomyosinIBA 12/2021 - 01/2018
4	Tyrosine Kinase InhibitorsIBA 10/2020 - 01/2017
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020 - 08/2017
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 03/2016
4	Carboplatin (JM8)FDA LinkGeneric 01/2018 - 04/2015
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2018 - 07/2014
3	selpercatinibIBA 01/2022 - 01/2019
3	tyrosine receptor (receptor, tyrosine)IBA 12/2021 - 11/2017
3	Fulvestrant (Faslodex)FDA Link 04/2021 - 01/2020
3	Protein Isoforms (Isoforms)IBA 01/2021 - 01/2018
3	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2018
3	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2018
3	Mitogen-Activated Protein KinasesIBA 01/2019 - 12/2015
3	ErbB Receptors (EGF Receptor)IBA 10/2018 - 12/2016
2	GenieIBA 01/2022 - 01/2020
2	Hormones (Hormone)IBA 01/2022 - 10/2018
2	DesminIBA 01/2021 - 01/2018
2	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2018
2	LY3023414IBA 01/2020 - 01/2018
2	LigandsIBA 09/2019 - 01/2018
2	NucleotidesIBA 01/2019 - 07/2017
2	Immune Checkpoint InhibitorsIBA 01/2019 - 01/2018
2	Bevacizumab (Avastin)FDA Link 01/2018 - 07/2014
2	NVP-BKM120IBA 12/2017 - 04/2015
2	taxaneIBA 12/2017 - 04/2015
2	zirconium-89-trastuzumabIBA 12/2017 - 10/2016
1	pertuzumabIBA 03/2024
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022
1	pirtobrutinibIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2022
1	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 04/2021
1	Everolimus FDA Link 01/2021
1	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 01/2021
1	MART-1 AntigenIBA 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2021
1	Topoisomerase II InhibitorsIBA 11/2020
1	Loperamide (Imodium)FDA LinkGeneric 10/2020
1	Exonucleases (3' 5' Exonuclease)IBA 01/2020
1	trastuzumab deruxtecanIBA 01/2020
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020
1	Protein Kinases (Protein Kinase)IBA 01/2020
1	Alanine Transaminase (SGPT)IBA 01/2020
1	Complement System Proteins (Complement)IBA 01/2020
1	Cytotoxins (Cytolysins)IBA 01/2020
1	ZirconiumIBA 01/2020
1	MitogensIBA 01/2020

Therapy/Procedure

48	Therapeutics 03/2024 - 02/2013
9	Drug Therapy (Chemotherapy) 01/2018 - 02/2013
6	Immunotherapy 01/2020 - 01/2018
2	Precision Medicine 07/2017 - 12/2015